A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight - PubMed (original) (raw)
doi: 10.1038/mp.2012.57. Epub 2012 May 29.
J-L Moreau, B Pouzet, R Mory, A Bradaia, D Buchy, V Metzler, S Chaboz, K Groebke Zbinden, G Galley, R D Norcross, D Tuerck, A Bruns, S R Morairty, T S Kilduff, T L Wallace, C Risterucci, J G Wettstein, M C Hoener
Affiliations
- PMID: 22641180
- DOI: 10.1038/mp.2012.57
A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight
F G Revel et al. Mol Psychiatry. 2013 May.
Abstract
Schizophrenia is a chronic, severe and highly complex mental illness. Current treatments manage the positive symptoms, yet have minimal effects on the negative and cognitive symptoms, two prominent features of the disease with critical impact on the long-term morbidity. In addition, antipsychotic treatments trigger serious side effects that precipitate treatment discontinuation. Here, we show that activation of the trace amine-associated receptor 1 (TAAR1), a modulator of monoaminergic neurotransmission, represents a novel therapeutic option. In rodents, activation of TAAR1 by two novel and pharmacologically distinct compounds, the full agonist RO5256390 and the partial agonist RO5263397, blocks psychostimulant-induced hyperactivity and produces a brain activation pattern reminiscent of the antipsychotic drug olanzapine, suggesting antipsychotic-like properties. TAAR1 agonists do not induce catalepsy or weight gain; RO5263397 even reduced haloperidol-induced catalepsy and prevented olanzapine from increasing body weight and fat accumulation. Finally, TAAR1 activation promotes vigilance in rats and shows pro-cognitive and antidepressant-like properties in rodent and primate models. These data suggest that TAAR1 agonists may provide a novel and differentiated treatment of schizophrenia as compared with current medication standards: TAAR1 agonists may improve not only the positive symptoms but also the negative symptoms and cognitive deficits, without causing adverse effects such as motor impairments or weight gain.
Similar articles
- TAAR1 agonists improve glycemic control, reduce body weight and modulate neurocircuits governing energy balance and feeding.
Dedic N, Wang L, Hajos-Korcsok E, Hecksher-Sørensen J, Roostalu U, Vickers SP, Wu S, Anacker C, Synan C, Jones PG, Milanovic S, Hopkins SC, Bristow LJ, Koblan KS. Dedic N, et al. Mol Metab. 2024 Feb;80:101883. doi: 10.1016/j.molmet.2024.101883. Epub 2024 Jan 16. Mol Metab. 2024. PMID: 38237896 Free PMC article. - Trace Amine-Associated Receptor 1 Agonists as Narcolepsy Therapeutics.
Black SW, Schwartz MD, Chen TM, Hoener MC, Kilduff TS. Black SW, et al. Biol Psychiatry. 2017 Nov 1;82(9):623-633. doi: 10.1016/j.biopsych.2016.10.012. Epub 2016 Oct 18. Biol Psychiatry. 2017. PMID: 27919403 Free PMC article. - Selective activation of the trace amine-associated receptor 1 decreases cocaine's reinforcing efficacy and prevents cocaine-induced changes in brain reward thresholds.
Pei Y, Mortas P, Hoener MC, Canales JJ. Pei Y, et al. Prog Neuropsychopharmacol Biol Psychiatry. 2015 Dec 3;63:70-5. doi: 10.1016/j.pnpbp.2015.05.014. Epub 2015 Jun 3. Prog Neuropsychopharmacol Biol Psychiatry. 2015. PMID: 26048337 - Therapeutic Potential of TAAR1 Agonists in Schizophrenia: Evidence from Preclinical Models and Clinical Studies.
Dedic N, Dworak H, Zeni C, Rutigliano G, Howes OD. Dedic N, et al. Int J Mol Sci. 2021 Dec 7;22(24):13185. doi: 10.3390/ijms222413185. Int J Mol Sci. 2021. PMID: 34947997 Free PMC article. Review. - Olanzapine: an updated review of its use in the management of schizophrenia.
Bhana N, Foster RH, Olney R, Plosker GL. Bhana N, et al. Drugs. 2001;61(1):111-61. doi: 10.2165/00003495-200161010-00011. Drugs. 2001. PMID: 11217867 Review.
Cited by
- Discovery and In Vivo Efficacy of Trace Amine-Associated Receptor 1 (TAAR1) Agonist 4-(2-Aminoethyl)-_N_-(3,5-dimethylphenyl)piperidine-1-carboxamide Hydrochloride (AP163) for the Treatment of Psychotic Disorders.
Krasavin M, Peshkov AA, Lukin A, Komarova K, Vinogradova L, Smirnova D, Kanov EV, Kuvarzin SR, Murtazina RZ, Efimova EV, Gureev M, Onokhin K, Zakharov K, Gainetdinov RR. Krasavin M, et al. Int J Mol Sci. 2022 Sep 30;23(19):11579. doi: 10.3390/ijms231911579. Int J Mol Sci. 2022. PMID: 36232878 Free PMC article. - Psychostimulant Use Disorder, an Unmet Therapeutic Goal: Can Modafinil Narrow the Gap?
Hersey M, Bacon AK, Bailey LG, Coggiano MA, Newman AH, Leggio L, Tanda G. Hersey M, et al. Front Neurosci. 2021 May 26;15:656475. doi: 10.3389/fnins.2021.656475. eCollection 2021. Front Neurosci. 2021. PMID: 34121988 Free PMC article. Review. - Effect of Co-Treatment of Olanzapine with SEP-363856 in Mice Models of Schizophrenia.
Liang L, Ren X, Xu J, Ma Y, Xue Y, Zhuang T, Zhang G. Liang L, et al. Molecules. 2022 Apr 14;27(8):2550. doi: 10.3390/molecules27082550. Molecules. 2022. PMID: 35458749 Free PMC article. - Unlocking the Therapeutic Potential of Ulotaront as a Trace Amine-Associated Receptor 1 Agonist for Neuropsychiatric Disorders.
Kuvarzin SR, Sukhanov I, Onokhin K, Zakharov K, Gainetdinov RR. Kuvarzin SR, et al. Biomedicines. 2023 Jul 13;11(7):1977. doi: 10.3390/biomedicines11071977. Biomedicines. 2023. PMID: 37509616 Free PMC article. Review. - TAAR1 Expression in Human Macrophages and Brain Tissue: A Potential Novel Facet of MS Neuroinflammation.
Barnes DA, Galloway DA, Hoener MC, Berry MD, Moore CS. Barnes DA, et al. Int J Mol Sci. 2021 Oct 27;22(21):11576. doi: 10.3390/ijms222111576. Int J Mol Sci. 2021. PMID: 34769007 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases